BURLINGAME, Calif.--(BUSINESS WIRE)--Urigen Pharmaceuticals, Inc. (OTCBB: URGP), http://www.urigen.com, today announced positive results from a multi-center, double-blind, placebo-controlled, crossover designed clinical trial of URG101 in patients with Painful Bladder Syndrome / Interstitial Cystitis (PBS/IC)
